A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
收藏DataCite Commons2025-11-24 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007068/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg)
versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the
prevention of relapse in participants with MDD who responded to acute treatment with
vortioxetine 10 mg.
提供机构：
Vivli
创建时间：
2021-04-20
